(FAGR) Fagron - Ratings and Ratios

Fagron NV is a pharmaceutical compounding company that provides personalized care to various healthcare institutions and individuals worldwide. With a diverse product portfolio, the company caters to a broad range of medical needs, from immune system regulation and hypopigmentation disorders to scar treatment and hair care. Its product lines, such as DiluCap, Imuno TF Complex, and Pentravan, demonstrate a commitment to innovative solutions that address specific patient requirements.

The companys business is segmented into Essentials, Brands, and Compounding Services, allowing for a structured approach to its operations. Fagrons commitment to education is evident through the Fagron Academy, which focuses on the professional development of prescribers and pharmacists. With a history dating back to 1990 and a name change from Arseus NV to Fagron NV in 2015, the company has established itself as a significant player in the pharmaceutical compounding industry.

From a technical analysis perspective, Fagron NVs stock (FAGR) is currently trading at €21.90, slightly above its 20-day Simple Moving Average (SMA) of €21.65 and significantly above its 200-day SMA of €18.78. The Average True Range (ATR) indicates a relatively low volatility of 1.44%. Given the current price is near its 52-week high of €22.10, the stock may be approaching a resistance level. A potential forecast based on technical indicators suggests that if the stock can break through the 52-week high, it may continue to rise, driven by momentum. Conversely, a drop below the 20-day SMA could signal a correction.

Fundamentally, Fagron NV boasts a market capitalization of €1598.77M, with a Price-to-Earnings (P/E) ratio of 19.95 and a forward P/E of 16.58, indicating a relatively stable valuation. The companys Return on Equity (RoE) stands at 32.24%, demonstrating strong profitability. Combining fundamental and technical insights, a forecast for Fagron NV could be that its stock will continue to perform well if it can maintain its current momentum and break through the 52-week high. However, investors should be cautious of potential corrections and keep a close eye on the stocks ability to stay above its moving averages. With its strong product portfolio and commitment to education, Fagron NV is well-positioned for continued growth in the pharmaceutical compounding sector.